Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Assay variability in serum prostate-specific antigen determination

M K Brawer1, P Daum, J C Petteway

  • 1Department of Urology, University of Washington, Seattle 98108, USA.

The Prostate
|July 1, 1995
PubMed
Summary

Serum prostate-specific antigen (PSA) assay consistency is crucial for early cancer detection. The IMx assay showed lower PSA values than the Tandem assay, especially in men with prostate cancer, indicating assay non-equivalence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of the Binding Energy on Nondipole Effects in Single-Photon Ionization.

Physical review letters·2024
Same author

Perioperative management of myasthenia gravis.

BJA education·2021
Same author

Effects of individual and combined dietary weight loss and exercise interventions in postmenopausal women on adiponectin and leptin levels.

Journal of internal medicine·2013
Same author

Influence of T-shift capsulorrhaphy on rotation and translation of the glenohumeral joint: An experimental study.

Journal of shoulder and elbow surgery·2012
Same author

Clinical Evidence: Non-metastatic prostate cancer.

The Western journal of medicine·2008
Same author

Modern brachytherapy for localized prostate cancers: the northwest hospital (Seattle) experience.

Reviews in urology·2006

Area of Science:

  • Clinical Chemistry
  • Biomarker Assay Validation
  • Prostate Cancer Diagnostics

Background:

  • Serum prostate-specific antigen (PSA) measurement is vital for prostate cancer screening and early detection.
  • Assay consistency and reproducibility are paramount for reliable PSA testing.
  • Different commercially available PSA assays may yield varying results, impacting clinical interpretation.

Purpose of the Study:

  • To compare the performance of the IMx assay and the Tandem E assay for serum PSA measurement.
  • To identify potential discrepancies in PSA values between the two assays, particularly in clinically relevant ranges.
  • To assess the impact of assay differences on the detection of prostate cancer.

Main Methods:

  • Investigated 228 archival sera using both IMx and Tandem E PSA assays.

Related Experiment Videos

  • Analyzed correlation coefficients (r²) and slopes across different PSA ranges (overall, 2.0-10.0 ng/ml, 2.0-6.0 ng/ml).
  • Evaluated PSA values using cutoffs of 4.0, 5.0, and 6.0 ng/ml to assess cancer detection rates.

    • Main Results:

    • A high overall correlation (r²=0.985) was observed, but it decreased in clinically relevant ranges (r²=0.923 for 2.0-10.0 ng/ml; r²=0.852 for 2.0-6.0 ng/ml).
    • The slope of the regression line also decreased in narrower ranges, indicating systematic differences.
    • The IMx assay yielded significantly lower abnormal PSA values compared to the Tandem assay, particularly in men with prostate cancer.

    Conclusions:

    • The IMx and Tandem E PSA assays are not equivalent and exhibit assay-specific biases.
    • The IMx assay tends to report lower PSA values than the Tandem assay, with a more pronounced effect in prostate cancer patients.
    • Clinicians and laboratories must be aware of the specific assay used and ensure assay consistency to avoid misinterpretation of PSA results.